Spots Global Cancer Trial Database for Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer

Official Title: A Phase II Study of ZD1839 (Iressa) Plus Anastrozole (Arimidex) in Patients With Relapsed Ovarian Cancer

Study ID: NCT00181688

Conditions

Ovarian Cancer

Peritoneal Carcinoma

Tubal Carcinoma

Interventions

Iressa (ZD1839)

Arimidex (Anastrozole)

Study Description

Brief Summary: The main purpose of this study is to determine the effects (good and bad) Iressa plus anastrozole has on patients with relapsed ovarian cancer.

Detailed Description: * Patients will receive Iressa and anastrozole orally once daily until treatment is ended. Treatment will end if any of the following occur: Unacceptable adverse effects; bowel obstruction; initiation of systemic chemotherapy; development of new ascites or pleural effusions, development of co-morbid disease or disease progression. * Patients will be given a drug log in which to record the date and time they take their pills, as well as any symptoms and concomitant medications. * Patients will be seen monthly for the following tests and procedures; a physical examination and repeat blood work. Patients who remain free of clinical symptoms should have repeat abdominal/pelvic CT scans and chest x-rays on an every 3 month basis.